Close Menu

Amgen

Decode is hoping to incorporate the recently discovered SNP on chromosome 4p16 into a multi-gene panel test for UBC, according to Decode's Kari Stefansson.

When Vectibix received approval from the US Food and Drug Administration in 2006, "Amgen already knew the response rate was low," according to an Amgen official. The company began collecting patient tissue samples from mid-2005 to early 2007, knowing it would "need those samples for a biomarker analysis."

"DxS is seeking to avoid its exclusive obligation with Roche because it no longer finds it advantageous to benefit from the Roche distribution network," but a termination of the agreement would cause "irreparable" harm, Roche stated in a recently filed complaint.

Most DTC genomic service providers use either custom or catalog chips made by the two West Coast vendors, though some vow to integrate next-gen sequencing into their services when cost and reliability issues improve.

DxS denies allegations in a lawsuit filed by Roche last week that the UK-based diagnostics company is trying to renege on a distribution agreement between the two firms for KRAS and EGFR mutations tests.

"Our data reinforce the importance of the KRAS mutation as a predictive biomarker for responsiveness to Vectibix therapy," said Roger Perlmutter, Amgen's executive vice president of research and development.

Decode is a longtime Illumina customer that has contributed content to several of its whole-genome genotyping chips. Some of its services, such as DecodeMe, have been offered on the Illumina BeadArray platform.

The newly formed Decode Genetics Ehf will continue all of Decode's human genetics operations and brand products and services. Meantime, the publicly traded entity known as Decode Genetics expects to be liquidated.

Saga Investments has financial backing from Arch Venture Partners and Polaris Venture Partners, both of which had previously invested in Decode.

A number of events and trends that arose last year, including the increasing prevalence of direct-to-consumer genomics firms and PGx programs initiated by pharmacy services providers, might just make 2009 the year personalized medicine really started to take hold in the public's mind.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.